After the termination of the agreements, Everest will continue to develop its own products utilizing the mRNA platform, and will own full intellectual property rights and full global rights of those products.
After the termination of the agreements, Everest will have full rights to all intellectual property rights provided, transferred, or made available by Providence to the Company prior to the effective date, and will have more flexibility going forward to develop products based on company strategy and goals. Everest will not need to pay milestone or royalty fees for products it develops in the future, except for the rabies or shingles vaccines which were developed in collaboration with Providence.
In
About
Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Contact:
Email: IR@everestmedicines.com
Email: PR@everestmedicines.com
(C) 2024 Electronic News Publishing, source